{'fraction_non_alphanumeric': 0.0231023102310231, 'fraction_numerical': 0.0297029702970297, 'mean_word_length': 5.7444444444444445, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cytochrome P450 CYP2C19 genotypes in Nigerian sickle‐cell disease patients and normal controls

Background and objective:  Subjects with different CYP2C19 genotypes may metabolize proguanil, a pro‐drug used for malaria prophylaxis differently and the frequency of the different alleles may be different in patients with sickle‐cell disease (SCD) and normal controls. The objective of this study was to evaluate CYP2C19 *1, *2 and *3 allele and genotype frequencies in Nigerian normal controls and SCD patients, and to further compare variant CYP2C19 frequencies in Nigerians with other African populations.